A first patient has been dosed in a Phase 2 trial investigating the safety and long-term efficacy of bryostatin-1 in treating moderate and moderately severe Alzheimer’s disease, the therapy’s developer, Neurotrope, announced. The trial (NCT04538066), which is recruiting patients at several sites across the U.S., will build on data from previous studies assessing bryostatin-1. Specifically, it is looking at the investigative therapy’s long-term effectiveness on aiding cognition in people not using Namenda (memantine), an approved Alzheimer’s treatment marketed…
You must be logged in to read/download the full post.
The post First Patient Dosed in Phase 2 Trial of Bryostatin-1 in Long-term Use appeared first on BioNewsFeeds.